Jarbøl, Dorte Ejg by unknown
Syddansk Universitet
Associations between patients' risk attitude and their adherence to statin treatment - a
population based questionnaire and register study
Barfoed, Benedicte Marie Lind; Paulsen, Maja Skov; Christensen, Palle Mark; Halvorsen,
Peder; Kjær, Trine; Larsen, Mogens Lytken ; Larsen, Pia Veldt; Nielsen, Jesper Bo;
Søndergaard, Jens; Jarbøl, Dorte Ejg
Published in:
BMC Family Practice
DOI:
10.1186/s12875-016-0423-1
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication
Citation for pulished version (APA):
Barfoed, B. M. L., Paulsen, M. S., Christensen, P. M., Halvorsen, P. A., Kjær, T., Larsen, M. L., ... Jarbøl, D. E.
(2016). Associations between patients' risk attitude and their adherence to statin treatment - a population based
questionnaire and register study. BMC Family Practice, 17, [28]. DOI: 10.1186/s12875-016-0423-1
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Jan. 2017
RESEARCH ARTICLE Open Access
Associations between patients’ risk attitude
and their adherence to statin treatment – a
population based questionnaire and register
study
Benedicte Lind Barfoed1* , Maja Skov Paulsen2, Palle Mark Christensen3, Peder Andreas Halvorsen4, Trine Kjær5,
Mogens Lytken Larsen6, Pia Veldt Larsen7,8, Jesper Bo Nielsen1, Jens Søndergaard1 and Dorte Ejg Jarbøl1
Abstract
Background: Poor adherence to medical treatment may have considerable consequences for the patients’ health
and for healthcare costs to society. The need to understand the determinants for poor adherence has motivated
several studies on socio-demographics and comorbidity. Few studies focus on the association between risk attitude
and adherence. The aim of the present study was to estimate associations between patients’ adherence to statin
treatment and different dimensions of risk attitude, and to identify subgroups of patients with poor adherence.
Methods: Population-based questionnaire and register-based study on a sample of 6393 persons of the general.
Danish population aged 20–79. Data on risk attitude were based on 4 items uncovering health-related as well as
financial dimensions of risk attitude. They were collected through a web-based questionnaire and combined with
register data on redeemed statin prescriptions, sociodemographics and comorbidity. Adherence was estimated by
proportion of days covered using a cut-off point at 80 %.
Results: For the dimension of health-related risk attitude, “Preference for GP visit when having symptoms”, risk-
neutral and risk-seeking patients had poorer adherence than the risk-averse patients, OR 0.80 (95 %-CI 0.68–0.95)
and OR 0.83 (95 %-CI 0.71–0.98), respectively. No significant association was found between adherence and financial
risk attitude. Further, patients in the youngest age group and patients with no CVD were less adherent to statin
treatment.
Conclusion: We find some indication that risk attitude is associated with adherence to statin treatment, and that
risk-neutral and risk-seeking patients may have poorer adherence than risk-averse patients. This is important for
clinicians to consider when discussing optimal treatment decisions with their patients. The identified subgroups
with the poorest adherence may deserve special attention from their GP regarding statin treatment.
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Background
Poor adherence to medical treatment may have consid-
erable consequences for patients’ health and for health-
care costs to society [1]. Adherence is a measure of the
degree to which the patient follows the treatment as
agreed with the doctor [2]. It is estimated that adherence
to long-term drug treatment of chronic disease is about
50 % in developed countries [3]. Adherence is par-
ticularly low for preventive therapy and for treatment
of diseases that do not cause symptoms perceivable to
the patient [4, 5]. It is well documented that patients’
comorbidity, co-medication, and socioeconomic status
are important determinants of poor adherence [6–8].
Furthermore qualitative research on adherence has fo-
cused on how persons’ everyday conditions such as
family life, holidays, and leisure schedules and societal
eating rules influence on the management of adher-
ence and adaptation of medical treatment [9, 10].
During the past decades the influence of risk attitude
on health behaviour and health outcome has received
little but an increasing attention in the literature [11–15].
Risk attitude is highly individual and can be influenced by
fear, sense of control, personal experiences, socioeconomic
conditions and the perceived severity of a condition
[16–19]. This study is one of the first to examine as-
sociations between risk attitude and adherence to sta-
tin treatment and to examine whether risk attitude
can explain some of the previous observed person-
specific heterogeneity by explicitly incorporating the
effect of risk attitude into our analysis of adherence
to statin treatment. The aim of the study was to esti-
mate associations between adherence and different di-
mensions of risk attitude, and to identify subgroups
with low adherence.
Methods
Sources of data
Data on risk attitude were obtained through a large
questionnaire study, The Danish Symptom Cohort, car-
ried out from June to December 2012 with the overall
aim of gaining knowledge of symptoms, healthcare-
seeking and related personality characteristics in the
adult Danish population. Prior to sending out the ques-
tionnaire, it was pilot tested in its entirety for content
validity, relevance, acceptability and feasibility. The data
quality, response rate, floor and ceiling effects, score
ranges, means and standard deviations of single items
and scores were assessed by a field test from the adult
Danish population. Details about the development of
the questionnaire are reported elsewhere [20]. The
study was designed as a nationwide cohort study of
100,000 persons aged 20 years or above from the gen-
eral Danish population with baseline data collected in a
web-based survey (Fig. 1). The median age of the
respondents was 52 years (interquartile range (IQR)
40–64) compared to 50 years (IQR) 36–66) for non-
respondents. Some 53.2 % of the respondents were
women compared to 48.6 of the non-respondents [21].
Eligible participants for the present study were be-
tween 20–79 years of age and had redeemed at least 2
prescriptions for statin treatment between 1 January
2012 and 31 December 2012.
Risk attitude
Risk attitude has previously been measured using case
vignettes and statements representing various attitudes
for the respondents to agree or disagree with [14, 18].
There is some indication that risk attitude might be
Fig. 1 Flowchart of patient sampling
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domain specific [19]. To allow for the measurement of
risk attitude in a broader perspective, we therefore chose
to elicit risk attitude in two domains, financial and
health-related. Financial risk attitude was measured by a
lottery choice experiment (Table 1), which has previ-
ously been shown to predict health behaviours such as
alcohol consumption, smoking, seat belt use [11] and pa-
tients’ treatment choice [22]. In order to elicit different
dimensions of health-related risk attitude three items
were developed specifically for this study, see Table 1.
Register data
The questionnaire data were combined with register
data from the Danish National Prescription Register
(DNPR), the National Patient Register (NPR), and demo-
graphic databases from Statistics Denmark. DNPR con-
tains data on all redeemed prescriptions in Denmark
since 1994 [23]. From the DNPR we included the fol-
lowing information for each redeemed prescription:
Identification of the dispensed product using the Ana-
tomical Therapeutic Chemical Classification System
(ATC), number of packages and pack size dispensed,
patients’ personal registration number and date of
prescription redemption. In order to estimate adher-
ence and duration of treatment we included data on
redeemed prescriptions for statin treatment (ATC
C10AA) from 1 January 1996 to 31 December 2012.
As markers of cardiovascular disease (CVD), we in-
cluded data on redeemed prescriptions for platelet ag-
gregation inhibitors (ATC B01AC04, −22 & -24) from
1 January 1996 to 31 December 2012. NPR contains
complete individual-level data from Danish hospitals
on all admissions since 1977 [24]; including date, hospital,
type of contact and diagnoses. From NPR we included
data on in-patient episodes of CVD from 1 January 1996
to 31 December 2013. From demographic databases from
Statistics Denmark we included data on highest attained
educational level, income, cohabitation status and labour
market status [25–27] in 2012.
Adherence
Adherence was measured as the proportion of days cov-
ered (PDC) [28], measuring the number of daily doses of
medication a patient has purchased relative to the length
of a defined study period. Since statin tablets exist in all
clinically relevant doses e.g. 10, 20, 40 and 80 mg, we
find it reasonable to assume that one tablet a day equals
one daily dose [29], rather than patients taking e.g. two
tablets or half a tablet a day. The study period was de-
fined as the time from index-date to end-date. For each
patient the index-date was the date of the first redeemed
prescription for a statin in 2012, and the end-date was
the date of the last redeemed prescription in the year
following the index date. This means that the end-date
could be any date in 2013 depending on the index-date
for the individual patient. A patient’s PDC was calcu-
lated by dividing the total number of tablets from all
redeemed prescriptions during the study period, exclud-
ing the redeemed prescription on the end-date, into the
number of days in the study period. Patients with a PDC
above 0.8 were categorised as adherent and patients with
a PDC equal to or below 0.8 as non-adherent [30].
Comorbidity
As comorbidity may be related to both risk attitude and
adherence it was considered a potential confounder. We
measured comorbidity in two different ways: General co-
morbidity using the Charlson Comorbidity Index [31]
and using CVD. The effect of CVD might be different
from general comorbidity, since patients with CVD may
be more likely to take statins than patients with other
comorbidities [32]. We therefore treated both Charlson
Table 1 Risk attitude items and response categories
Item wording Risk-averse Risk-neutral Risk-seeking
Imagine that you unexpectedly inherited DKK 10,000
(approximately USD 2,000) from a distant relative.
Subsequently you have the possibility of participating
in a lottery with an equal chance of doubling the money
or losing the money. That means that there is a 50 %
chance of you winning DKK 20,000 and a 50 % chance
of losing the DKK 10,000.
I choose not to participate in the lottery I do not know I choose to participate in the lottery
What do you choose? (abbreviated: “Financial”)
I focus a lot on having a healthy behaviour and prefer
to avoid risks that can affect my health. (abbreviated:
“Focus on healthy behaviour”)
Completely agree Tend to agree Yes and no Tend to disagree Completely disagree
When I experience symptoms, I generally count on them
passing. (abbreviated: “Count on symptoms passing”)
Completely disagree Tend to disagree Yes and no Tend to agree Completely agree
I do not like to take chances regarding my health and
prefer to see my GP once too often than once too late.
(abbreviated: “Preference for GP contact regarding my health”)
Completely agree Tend to agree Yes and no Tend to disagree Completely disagree
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Comorbidity index and CVD as confounders in the ana-
lyses as proposed by Benner et al. [32].
The NPR was used to calculate the Charlson Comor-
bidity Index for each patient and to identify patients
with CVD. Patients were categorised as having CVD, if
they had 1) been admitted with diagnoses of stroke,
acute coronary syndrome and/or complications and an-
gina or had undergone coronary bypass graft or percu-
taneous coronary intervention or 2) had redeemed a
prescription for clopidogrel, prasugrel and ticagrelor,
platelet aggregation inhibitors used as secondary preven-
tion to prevent new myocardiac infarction.
Statistical methods
For each of the 4 risk attitude items, responses were
categorised into 3 groups: “Risk-seeking”, “risk-averse”
and “risk-neutral” (Table 1) according to the terminology
used in standard economic theory [33]. Logistic regres-
sion was used to estimate associations between adher-
ence and each of the 4 risk attitude dimensions, as well
as age group (20–39 years, 40–59 years, 60–79 years),
gender, highest attained educational level (<10 years,
10–12 years, >12 years), income (1st quartile, 2nd + 3rd
quartile, 4th quartile), cohabitation (single, married/co-
habiting) labour market status (working, retirement pen-
sion, not in the workforce), duration of treatment
(<1 year, 1–2 years, 2–5 years, 5–10 years, >10 years),
Charlson Comorbidity Index and CVD [34, 35].
The analyses were adjusted for age, gender, highest
attained educational level and cohabitation, the Charlson
Comorbidity Index and CVD. Missing values were
considered missing at random. STATA release 13.0
(StatCorp, College Station, TX) was used for all statis-
tical analyses.
Results
Of the 49,706 initial respondents to the Danish Symp-
tom Cohort, some 6755 patients met the inclusion
criteria for the present study. Of the 6755 patients
359 redeemed only one statin prescription in 2012,
leaving 6396 patients eligible for adherence analyses
(Fig. 1 & Table 2).
For the financial risk attitude item, some 5188 pa-
tients (81.1 %) were categorised as risk-averse. For
the risk attitude items “Focus on healthy behaviour”,
“Count on symptoms passing” and “Preference for GP
contact regarding my health”, 4153 (64.9 %), 776
(12.1 %) and 3572 (55.9 %) patients, respectively, were
categorised as risk averse (Table 2).
Overall, some 5280 (82.6 %) of the 6396 respondents
were adherent to their medication with statins. For the
risk attitude dimension “Preference for GP contact re-
garding my health”, the risk-neutral and risk-seeking
patients had significantly poorer adherence than the
risk-averse patients, OR 0.80 (95 %-CI 0.68–0.95) and
OR 0.83 (95 %-CI 0.71–0.98), respectively (Table 3).
The dimensions of financial risk attitude and the risk
attitude dimensions “Focus on healthy behaviour” and
“Count on symptoms passing” were not significantly as-
sociated with adherence. Patients in the youngest age
group had poorer adherence than older patients OR
2.61 (95 % CI 1.52–4.47), and patients in the workforce
had poorer adherence than patients on retirement pen-
sion OR 1.32 (95 %-CI 1.14–1.52). Respondents with
CVD had better adherence to treatment, OR 1.36
(95 %-CI 1.11–1.67) compared to respondents without
CVD (Table 4).
Kendall’s tau correlation between CVD and the
Charlson Comorbidity Index was low (τ = 0.29). The
interactions between risk attitude, CVD and Charlson
Comorbidity Index, respectively, and adherence were
insignificant (p-values 0.607 and 0.827).
Discussion
Summary findings
The present study considered associations between ad-
herence and four different dimensions of risk attitude
in relation to health and finance. Significant associa-
tions were found between the risk attitude for the
health dimension “Preference for healthcare-seeking
when having symptoms” and adherence to statin treat-
ment, where risk-neutral and risk-seeking patients had
poorer adherence than risk-averse patients. No associa-
tions were found between adherence and the other di-
mensions of risk attitude. Patients in the youngest age
group and patients without CVD were the least adher-
ent. Patients on retirement pension were more adher-
ent than patients in the workforce.
Implications for practice and future research
Statins are only beneficial, if patients use them con-
sistently and long-term. If risk attitude is an un-
changeable personality characteristic, maybe clinicians
should support some risk-seeking patients in not
using statins instead of using them with poor adher-
ence. Here interventions to help clinicians communi-
cate adequately with their patients about risks and
benefits of medical treatment and involving patients
in decisions to prescribe medical treatment are rec-
ommended to enhance adherence [8].
Literature addressing the relationship between risk at-
titude and adherence to medical treatment choice is
sparse, but a few studies focus on related topics. Prosser
et al. found that the more risk-seeking an individual is,
the more likely he or she is to choose no treatment [22],
but the study is limited by a small sample size and self-
reported adherence. King et al. studied associations be-
tween risk-taking attitude and cardiac care in a large
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cohort study and suggest that patients’ risk attitude
may contribute to differences in the use of cardiac
procedures [36]. The study of King et al. is relevant
to our findings as adherence might be considered as
a step on the causal pathway between risk attitude
and cardiac care. Our results are in line with Benner
et al. finding that patients with CVD were signifi-
cantly more adherent to statin treatment than pa-
tients with no CVD [32]. This may be a result of
some cardiovascular conditions causing symptoms
which the patients perceive as severe and which
might induce them to be more careful with their
daily medication intake and thus more adherent as
suggested by the WHO [1].
Questionnaires are a common way of measuring person-
ality characteristics such as risk attitude [18, 19, 36, 37], but
they might be impractical to use in everyday clinical
practice. The present findings could, however, serve as
inspiration in developing a tool to be used by GPs in
the clinical consultation in order to guide them about
likely adherence. Other interesting issues for future re-
search would be to explore associations between risk
attitude and primary non-adherence and/or early dis-
continuation of treatment i.e. patients who decides not
to embark on statin treatment while having received a
prescription or patients who abandon treatment after
having redeemed their first prescription.
The present findings support previous research in
underlining that clinicians should consider potential
adherence issues when discussing optimal treatment
decisions with their patients. Further, the least adher-
ent subgroups may deserve special attention from
their GP. Targeting clinicians’ attention to these pa-
tient groups may improve adherence on a more gen-
eral basis. Thus it is possible that the findings
regarding adherence might be transferred to other
areas such as other asymptomatic conditions, vaccin-
ation and screening programmes.
Table 2 Distribution of risk attitude, socioeconomic factors,
duration of treatment and comorbidity, n = 6396*
N (%)
Risk attitude, Financial
Risk-averse 5188 (81.1)
Risk-neutral 512 (8.0)
Risk-seeking 696 (10.9)
Risk attitude, health: Focus on healthy behaviour
Risk-averse 4153 (64.9)
Risk-neutral 1436 (22.5)
Risk-seeking 807 (12.6)
Risk attitude, health: Count on symptoms passing
Risk-averse 776 (12.1)
Risk-neutral 591 (9.2)
Risk-seeking 5029 (78.6)
Risk attitude, health: Preference for GP contact regarding
my health
Risk-averse 3572 (55.9)
Risk-neutral 1244 (19.5)
Risk-seeking 1580 (24.7)
Gender
Male 3544 (55.4)
Female 2852 (44.5)
Age (years)
20–39 70 (1.1)
40–59 1781 (27.9)
60–79 4545 (71.1)
Income
Low (1st quartile) 957 (15.0)
Medium (2nd + 3rd quartile) 3504 (54.8)
High (4th quartile) 1933 (30.2)
Highest attained educational level (years)
< 10 1757 (27.9)
10–12 2992 (47.5)
> 12 1551 (24.6)
Cohabitation status
Single 1399 (21.9)
Married/cohabiting 4995 (78.1)
Labour market status
Working 2574 (40.2)
Retirement pension 3193 (49.9)
Not in the workforce 629 (9.8)
Duration of statin treatment
< 1 year 539 (8.4)
1–2 years 547 (8.6)
2–5 years 3089 (48.3)
5–10 years 1526 (23.9)
Table 2 Distribution of risk attitude, socioeconomic factors,
duration of treatment and comorbidity, n = 6396* (Continued)
< 10 years 695 (10.9)
Comorbidity
CVD
No CVD 5340 (83.5)
CVD 1056 (16.5)
Charlson
None 3593 (55.6)
1 1491 (23.8)
≥ 2 1289 (20.6)
*Up to 1.5 % missings in registers
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Strengths and limitations
We chose to study patients with cardiovascular risk and
statin treatment since dyslipidemia is a chronic and
asymptomatic condition and represents a major modifi-
able cardiovascular risk factor which can be reduced
with statins to decrease overall cardiovascular risk [38].
Further, statins are usually administered as one tablet
daily, which makes pharmocoepidemiological analysis
more straightforward than for drugs with more complex
administrations.
A major strength of the study is the large representa-
tive sample from the general Danish population obtained
through the Danish Symptom Cohort. Further, in this
study we estimated adherence using valid registers of
on-going prescription redemption, which is considered a
fairly accurate way of estimating actual medication use
in large populations [28]. A broad range of measures of
adherence using prescription databases exists [39]. The
method of PDC has several advantages: It includes a di-
mension of long-term use in the analysis by defining the
proportion of days the patient has tablets available over
a long period. It measures the degree of perseverance
and consistency in daily medication taking behaviour. By
using adherence and PDC with a fixed cut-off point, we
elucidate contrasts between those patients who are ad-
herent on a daily basis and those who are not [40].
In the analyses, we adjusted for two types of comorbid-
ity, general comorbidity using the Charlson Comorbidity
Index and CVD. However, we were unable to adjust
for psychiatric comorbidity such as depression. Con-
sequently, we cannot rule out that this may have con-
founded our results.
The response rate to the Danish Symptom Cohort
questionnaire was 52.2 %, which may raise the question
whether risk-averse patients might be more likely to
complete the questionnaire thus introducing a source of
bias into the results. As in most questionnaire studies,
the response-rate could be a limitation. However, risk
attitude is considered to be more dependent on age
and gender [41], and these characteristics were well
balanced between respondents and non-respondents.
To elicit the different dimensions of risk attitude, the
items were constructed in different ways: Both a case
vignette (a lottery), as the financial risk attitude item,
and statements representing various health risk atti-
tudes that the respondents were asked to agree or
disagree with were used. The application of different
item constructs strengthened the basis for estimating
risk attitude. For the risk attitude on health “Count
on symptoms passing”, the responses “completely
agree” or “mostly agree” were categorised as risk-
seeking (see Table 1). It may be argued that the
wording of this statement might imply a degree of
prudence in the way that some extent of patience
with emerging symptoms before healthcare seeking
may be perceived as wise. The wording of the risk
Table 3 Associations between risk attitude and adherence (PDC > 80 %*), n = 6396**
Proportion of adherent patients (%) OR crude (95 % CI) P-value OR adj.*** (95 % CI) P-value
Risk attitude, Financial
Risk-averse 4291/5188 (82.7) 1 1
Risk-neutral 421/512 (82.2) 0.97 (0.76–1.23) 0.783 0.93 (0.73–1.19) 0.560
Risk-seeking 568/696 (81.6) 0.93 (0.76–1.14) 0.472 0.94 (0.76–1.16) 0.562
Risk attitude, health:
Focus on healthy behaviour
Risk-averse 3464/4153 (83.4) 1 1
Risk-neutral 1167/1436 (81.3) 0.86 (0.74–1.01) 0.064 0.88 (0.75–1.03) 0.116
Risk-seeking 649/807 (80.4) 0.82 (0.67–0.99) 0.039 0.84 (0.69–1.03) 0.096
Risk attitude, health: Count on symptoms passing
Risk-averse 644/776 (83.0) 1 1
Risk-neutral 489/591 (82.7) 0.98 (0.74–1.31) 0.904 0.99 (0.74–1.33) 0.948
Risk-seeking 4147/5029 (82.5) 0.96 (0.79–1.18) 0.718 0.91 (0.74–1.13) 0.395
Risk attitude, health: Preference for GP contact
regarding my health
Risk-averse 2996/3572 (83.8) 1 1
Risk-neutral 1000/1244 (80.4) 0.79 (0.67–0.93) 0.005 0.80 (0.68–0.95) 0.011
Risk-seeking 1284/1580 (82.6) 0.83 (0.71–0.97) 0.021 0.83 (0.71–0.98) 0.025
*Adherence was defined as a PDC (proportion of days covered) above 80 %
**Up to 1.5 % of the data were missing in registers
***We adjusted for age group, Charlson Comorbidity Index and CVD, highest attained educational level, cohabitation status and duration of statin treatment
Barfoed et al. BMC Family Practice  (2016) 17:28 Page 6 of 9
attitude on health “Preference for GP contact regard-
ing my health” could be perceived as leading encour-
aging people to disagree to take chances and see a
GP to late. Yet we see great variation in the
responses to that item with 44.2 % answering “yes
and no”, “tend to disagree” or “completely disagree”
and thereby being categorised as risk-neutral or risk-
seeking.
Table 4 Associations between adherence (PDC > 80 %*) and socioeconomic factors, cohabitation, duration of treatment and
comorbidity, respectively n = 6396**
Proportion of adherent patients (%) OR crude (95 % CI) P-value OR adj.*** (95 % CI) P-value
Gender
Male 2903/3544 (81.9) 1 1
Female 2372/2852 (83.2) 1.08 (0.95–1.23) 0.243 1.13 (0.98–1.29) 0.089
Age (years)
20–39 47/70 (32.9) 1 1
40–59 1429/1781 (80.2) 1.99 (1.19–3.32) 0.009 2.20 (1.28–3.78) 0.004
60–79 3804/4545 (83.7) 2.51 (1.51–4.16) <0.001 2.61 (1.52–4.47) <0.001
Income
Low (1st quartile) 807/957 (84.3) 1 1
Medium (2nd + 3rd quartile) 2916/3504 (83.2) 0.92 (0.75–1.12) 0.414 0.93 (0.76–1.15) 0.508
High (4th quartile) 1555/1933 (80.4) 0.76 (0.62–0.94) 0.011 0.82 (0.65–1.04) 0.098
Highest attained educational level (years)
< 10 1474/1757 (83.9) 1 1
10–12 2470/2992 (82.6) 0.91 (0.78–1.06) 0.235 0.93 (0.79–1.10) 0.405
> 12 1256/1551 (81.0) 0.82 (0.68–0.98) 0.028 0.85 (0.71–1.02) 0.088
Cohabitation status
Single 1157/1399 (82.7) 1 1
Married/cohabiting 4121/4995 (82.5) 0.99 (0.84–1.15) 0.862 1.01 (0.86–1.19) 0.901
Labour market status****
Working 2054/2574 (79.8) 1 1
Retirement pension 2700/3193 (84.6) 1.37 (1.21–1.59) <0.001 1.32 (1.14–1.52) <0.001
Not in the workforce 526/629 (83.6) 1.29 (1.03–1.63) 0.030 1.25 (0.99–1.59) 0.064
Duration of statin treatment
< 1 year 456/539 (84.6) 1
1–2 years 447/547 (81.7) 0.81 (0.59–1.12) 0.205 0.82 (0.59–1.14) 0.244
2–5 years 2490/3089 (80.6) 0.76 (0.59–0.97) 0.029 0.74 (0.57–0.96) 0.024
5–10 years 1290/1526 (84.5) 0.99 (0.76–1.31) 0.971 0.95 (0.72–1.27) 0.741
> 10 years 597/695 (85.9) 1.12 (0.81–1.52) 0.523 1.02 (0.73–1.41) 0.924
Comorbidity
CVD
No CVD 4366/5340 (81.8) 1 1
CVD 914/1056 (86.6) 1.43 (1.19–1.74) <0.001 1.36 (1.11–1.67) 0.003
Charlson
None 2858/3593 (81.8) 1 1
1 1240/1491 (83.2) 1.10 (0.93–1.29) 0.256 1.00 (0.84–1.18) 0.984
≥ 2 1089/1289 (84.5) 1.21 (1.02–1.44) 0.032 1.07 (0.89–1.28) 0.464
*Adherence was defined as a PDC (proportion of days covered) above 80 %
**Up to 1.5 % of the data were missing in registers
***We adjusted for age group, Charlson Comorbidity Index and CVD, highest attained educational level, cohabitation status and duration of statin treatment
****Labour market status was not adjusted for age group because of the close correlation
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Conclusion
We found that the risk-seeking, the young and those
without CVD were less likely to be adherent to statin
therapy. The association between risk attitude and ad-
herence was found for one of the three dimensions of
health-related risk attitude, “Preference for GP visit
when having symptoms”, but not for risk attitude in the
financial domain. To the extent that our findings are
confirmed in future studies, health related risk attitude
might become an important issue in conversations be-
tween patients and their GPs.
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